Market Summary
USD66.85-2.68
Market Closed-3.85%
EXAS Stock Price
EXAS RSI Chart
EXAS Valuation
EXAS Price/Sales (Trailing)
EXAS Profitability
EXAS Fundamentals
EXAS Revenue
EXAS Earnings
Price Action
52 Week Range
29.27100.77
(Low)(High)
Last 7 days
-12.8%
Last 30 days
-21.0%
Last 90 days
-27.8%
Trailing 12 Months
94.6%
EXAS Financial Health
EXAS Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for EXAS
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-01 | Condella Sarah | gifted | - | - | -2,391 | evp, human resources |
2023-09-01 | Condella Sarah | sold | -379,620 | 84.36 | -4,500 | evp, human resources |
2023-08-21 | Elliott Jeffrey Thomas | sold | -2,505,010 | 82.92 | -30,210 | chief financial officer |
2023-08-07 | Baranick Brian | sold | -114,804 | 85.04 | -1,350 | gen. mgr., precision oncology |
2023-08-04 | Baranick Brian | acquired | - | - | 2,712 | gen. mgr., precision oncology |
2023-07-27 | Doyle James Edward | sold | -194,840 | 97.42 | -2,000 | - |
2023-07-19 | Herriott James | sold | -130,000 | 100 | -1,300 | general counsel |
2023-06-09 | Doyle James Edward | sold | -126,895 | 90.51 | -1,402 | - |
2023-06-09 | Zanotti Katherine S | sold | -273,974 | 90.51 | -3,027 | - |
2023-06-08 | Sebelius Kathleen | acquired | - | - | 3,599 | - |
Which funds bought or sold EXAS recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-21 | Jefferies Group LLC | new | - | 454,860 | 454,860 | -% |
2023-09-20 | BARCLAYS PLC | reduced | -9.07 | 3,534,000 | 17,170,000 | 0.01% |
2023-09-12 | Farther Finance Advisors, LLC | added | 58.18 | 35,518 | 65,354 | 0.01% |
2023-09-07 | ST GERMAIN D J CO INC | new | - | 46,481 | 46,481 | -% |
2023-08-30 | Strait & Sound Wealth Management LLC | added | 0.08 | 503,995 | 1,810,020 | 1.79% |
2023-08-29 | EFG Asset Management (Americas) Corp. | reduced | -6.23 | 65,888 | 286,677 | 0.07% |
2023-08-24 | Arlington Capital Management, Inc. | added | 57.62 | 957,667 | 1,767,390 | 1.53% |
2023-08-24 | Alberta Investment Management Corp | unchanged | - | 114,796 | 413,160 | -% |
2023-08-22 | COMERICA BANK | new | - | - | - | -% |
2023-08-22 | COMERICA BANK | new | - | 57,000 | 57,000 | 0.01% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Exact Sciences
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 10, 2023 | ark investment management llc | 9.03% | 16,040,490 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.71% | 17,252,465 | SC 13G/A | |
| Feb 07, 2023 | blackrock inc. | 6.4% | 11,354,134 | SC 13G/A | |
| Feb 06, 2023 | wellington management group llp | 5.86% | 10,404,476 | SC 13G/A | |
| Sep 12, 2022 | price t rowe associates inc /md/ | 3.7% | 6,464,337 | SC 13G/A | |
| Mar 10, 2022 | price t rowe associates inc /md/ | 10.7% | 18,724,736 | SC 13G/A | |
| Feb 14, 2022 | price t rowe associates inc /md/ | 8.0% | 13,788,133 | SC 13G/A | |
| Feb 11, 2022 | capital world investors | 2.7% | 4,682,850 | SC 13G/A | |
| Feb 09, 2022 | ark investment management llc | 7.83% | 13,496,014 | SC 13G | |
| Feb 04, 2022 | blackrock inc. | 5.5% | 9,497,012 | SC 13G |
Recent SEC filings of Exact Sciences
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 01, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 23, 2023 | 4 | Insider Trading | |
| Aug 21, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 08, 2023 | 4 | Insider Trading | |
| Aug 07, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 01, 2023 | S-8 | Employee Benefits Plan | |
| Aug 01, 2023 | 8-K | Current Report | |
| Aug 01, 2023 | 10-Q | Quarterly Report | |
| Jul 28, 2023 | 4 | Insider Trading |
Peers (Alternatives to Exact Sciences)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
GILD | 93.5B | 27.4B | -2.63% | 19.73% | 17.06 | 3.42 | -0.48% | 32.56% |
MRNA | 38.1B | 10.7B | -13.40% | -19.57% | 31.56 | 3.58 | -53.67% | -91.41% |
INCY | 13.0B | 3.5B | -10.13% | -13.81% | 35.41 | 3.69 | 5.81% | -61.22% |
EXAS | 12.1B | 2.3B | -20.97% | 94.61% | -27.96 | 5.25 | 18.69% | 41.23% |
| MID-CAP | ||||||||
EXEL | 6.9B | 1.7B | -1.24% | 29.63% | 41.88 | 4.01 | 10.25% | -39.75% |
SYNH | 4.4B | 5.4B | 0.61% | -11.20% | 62.22 | 0.82 | 0.01% | -74.39% |
DNLI | 3.0B | - | -2.68% | -18.72% | -23.7 | 37.44 | 122.90% | 54.78% |
ARWR | 2.9B | 256.2M | -4.82% | -13.52% | -16.11 | 11.39 | 2.51% | -17.66% |
| SMALL-CAP | ||||||||
NVAX | 672.4M | 1.6B | -20.87% | -68.23% | -1.15 | 0.42 | 23.74% | 60.24% |
AVXL | 560.8M | - | -14.09% | -26.23% | -10.86 | 6.7K | - | -13.75% |
PGEN | 357.7M | 22.1M | -16.67% | -40.68% | 16.15 | 16.18 | 43.14% | 124.16% |
SRNE | 170.9M | 66.2M | -71.28% | -88.95% | -0.25 | 2.73 | 20.37% | -7.56% |
NNVC | 14.9M | - | -20.01% | -20.99% | -2.2 | - | - | 19.06% |
TENX | 6.8M | 559.4K | -28.74% | -92.61% | -0.36 | 12.16 | - | 69.86% |
Exact Sciences News
Returns for EXAS
Cumulative Returns on EXAS
18.5%
10-Year Cumulative Returns
18.7%
7-Year Cumulative Returns
-2.6%
5-Year Cumulative Returns
-2.9%
3-Year Cumulative Returns
Risks for EXAS
What is the probability of a big loss on EXAS?
100%
Probability that Exact Sciences stock will be more than 20% underwater in next one year
76.2%
Probability that Exact Sciences stock will be more than 30% underwater in next one year.
55%
Probability that Exact Sciences stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does EXAS drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Exact Sciences was unfortunately bought at previous high price.
Drawdowns
Financials for Exact Sciences
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 4.6% | 2,300,611,000 | 2,200,158,000 | 2,084,279,000 | 2,005,096,000 | 1,938,402,000 | 1,851,581,000 | 1,767,087,000 | 1,759,614,000 | 1,711,598,000 | 1,545,647,000 | 1,491,391,000 | 1,320,627,000 | 1,131,069,000 | 1,062,071,000 | 876,293,000 | 723,699,000 | 623,185,000 | 526,209,000 | 454,462,000 | 398,887,000 | 353,170,000 |
| Cost Of Revenue | 2.1% | 608,946,000 | 596,555,000 | 574,394,000 | 546,300,000 | 514,101,000 | 483,469,000 | 458,757,000 | 439,464,000 | 418,787,000 | 382,711,000 | 354,324,000 | 324,975,000 | 282,249,000 | 255,496,000 | 216,717,000 | 184,128,000 | 161,478,000 | 136,892,000 | 116,644,000 | 102,312,000 | 93,356,000 |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 537,965,000 | 460,190,000 | 387,889,000 | 336,480,000 | 295,570,000 | 259,144,000 |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 724,955,000 | 652,445,000 | 579,026,000 | 495,951,000 | 428,714,000 | 379,774,000 |
| S&GA Expenses | -4.9% | 761,362,000 | 800,794,000 | 846,011,000 | 920,104,000 | 929,024,000 | 907,929,000 | 861,889,000 | 744,412,000 | 684,276,000 | 608,311,000 | 589,919,000 | 542,943,000 | 492,658,000 | 461,986,000 | 385,176,000 | 342,098,000 | 320,738,000 | 286,979,000 | 249,448,000 | 213,302,000 | 186,234,000 |
| R&D Expenses | -0.5% | 384,601,000 | 386,589,000 | 393,418,000 | 387,586,000 | 372,129,000 | 372,281,000 | 385,600,000 | 743,557,000 | 699,672,000 | 626,110,000 | 554,052,000 | 150,876,000 | 154,119,000 | 151,418,000 | 139,694,000 | 117,171,000 | 99,857,000 | 84,366,000 | 67,285,000 | 59,260,000 | 53,585,000 |
| EBITDA | 100.0% | - | -390,806,333 | - | -611,176,333 | -633,140,333 | -644,919,000 | -738,600,000 | -821,280,000 | -896,580,000 | -790,197,666 | -689,995,333 | -542,297,333 | -381,703,666 | -374,505,666 | -301,450,000 | -246,018,000 | - | - | - | - | - |
| EBITDA Margin | 100.0% | - | -0.18 | - | -0.30 | -0.44 | -0.35 | -0.42 | -0.47 | -0.52 | -0.51 | -0.46 | -0.41 | -0.34 | -0.35 | -0.34 | -0.34 | - | - | - | - | - |
| Interest Expenses | -11.7% | 24,912,000 | 28,219,000 | 19,634,000 | 18,330,000 | 18,885,000 | 18,744,000 | 18,606,000 | 117,375,000 | 117,577,000 | 117,929,000 | 67,941,000 | -77,070,000 | -85,801,000 | -94,213,000 | -61,599,000 | -58,883,000 | -56,378,000 | -52,269,000 | -36,789,000 | -25,868,000 | -15,215,000 |
| Earnings Before Taxes | 16.8% | -434,217,000 | -522,112,000 | -632,570,000 | -727,497,000 | -746,416,000 | -751,489,000 | -842,506,000 | -1,036,148,000 | -1,070,642,000 | -966,152,000 | -829,063,000 | -517,250,000 | -351,802,000 | -322,350,000 | -268,879,000 | -216,163,000 | -221,658,000 | -219,101,000 | -175,057,000 | -142,810,000 | -124,601,000 |
| EBT Margin | 100.0% | - | -0.24 | -0.30 | -0.36 | -0.52 | -0.41 | -0.48 | -0.58 | -0.63 | -0.64 | -0.56 | -0.41 | -0.31 | -0.30 | -0.31 | - | - | - | - | - | - |
| Net Income | 16.5% | -431,683,000 | -516,720,000 | -623,506,000 | -716,372,000 | -734,549,000 | -745,398,000 | -595,625,000 | -793,346,000 | -828,946,000 | -720,126,000 | -823,605,000 | -327,300,000 | -165,287,000 | -135,697,000 | -83,993,000 | -215,940,000 | -220,779,000 | -218,664,000 | -175,149,000 | -142,939,000 | -124,472,000 |
| Net Income Margin | 100.0% | - | -0.23 | -0.30 | -0.36 | -0.51 | -0.40 | -0.34 | -0.45 | -0.48 | -0.48 | -0.56 | -0.26 | -0.16 | -0.13 | -0.10 | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -298,219,000 | -438,021,000 | -501,146,000 | -495,227,000 | -355,232,000 | -238,002,000 | -59,204,000 | 87,888,000 | 43,769,000 | 71,404,000 | -89,426,000 | -237,704,000 | -261,158,000 | -283,457,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 0.8% | 6,356 | 6,304 | 6,227 | 6,307 | 6,437 | 6,491 | 6,685 | 6,654 | 6,724 | 6,735 | 4,925 | 4,354 | 4,468 | 4,461 | 3,506 | 1,759 | 1,782 | 1,771 | 1,524 | 1,510 | 1,483 |
| Current Assets | 7.6% | 1,174 | 1,091 | 982 | 1,049 | 1,102 | 1,215 | 1,426 | 1,616 | 1,669 | 1,775 | 2,199 | 1,607 | 1,505 | 1,484 | 554 | 1,320 | 1,375 | 1,407 | 1,228 | 1,290 | 1,310 |
| Cash Equivalents | 43.4% | 604 | 421 | 242 | 235 | 213 | 190 | 316 | 274 | 364 | 1,104 | 1,491 | 807 | 704 | 701 | 178 | 1,034 | 205 | 285 | 160 | 162 | 226 |
| Inventory | 5.4% | 131 | 124 | 118 | 115 | 115 | 113 | 105 | 95.00 | 90.00 | 89.00 | 92.00 | 80.00 | 82.00 | 69.00 | 62.00 | 54.00 | 48.00 | 44.00 | 39.00 | 39.00 | 35.00 |
| Net PPE | - | - | - | 685 | - | - | 623 | 580 | 524 | 502 | 483 | 452 | 456 | 463 | 465 | 455 | 371 | 335 | 292 | 245 | 188 | 140 |
| Goodwill | 0.0% | 2,346 | 2,346 | 2,346 | 2,345 | 2,346 | 2,335 | 2,335 | 2,243 | 2,243 | 57.00 | 1,238 | 1,238 | 1,238 | 30.00 | 1,203 | - | - | - | 15.00 | - | - |
| Liabilities | 1.6% | 3,299 | 3,247 | 3,184 | 3,198 | 3,228 | 3,232 | 3,297 | 3,197 | 3,165 | 3,086 | 2,690 | 2,017 | 1,957 | 1,923 | 1,218 | 1,011 | 1,016 | 994 | 843 | 793 | 738 |
| Current Liabilities | 32.9% | 488 | 367 | 413 | 424 | 443 | 481 | 517 | 710 | 676 | 629 | 633 | 253 | 222 | 244 | 236 | 481 | 492 | 168 | 136 | 107 | 83.00 |
| LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00 | - | - | 0.00 | 0.00 | - | 5.00 |
| LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.00 | - | - | 25.00 | 24.00 | 17.00 | 1.00 |
| Shareholder's Equity | 0.0% | 3,057 | 3,058 | 3,043 | 3,109 | 3,209 | 3,258 | 3,388 | 3,458 | 3,559 | 3,649 | 2,236 | 1,731 | 1,887 | 1,896 | 1,958 | 748 | 766 | 777 | 447 | 717 | 744 |
| Retained Earnings | -2.4% | -3,420 | -3,339 | -3,265 | -3,137 | -2,988 | -2,822 | -2,641 | -2,420 | -2,253 | -2,077 | -2,045 | -1,531 | -1,311 | -1,225 | -1,119 | -1,197 | -1,157 | -1,118 | -1,035 | -981 | -936 |
| Additional Paid-In Capital | 1.2% | 6,476 | 6,397 | 6,312 | 6,255 | 6,205 | 6,086 | 6,029 | 5,877 | 5,811 | 5,724 | 4,279 | 3,866 | 3,820 | 3,763 | 3,406 | 1,945 | 1,920 | 1,894 | 1,717 | 1,699 | 1,681 |
| Shares Outstanding | 0.4% | 181 | 180 | 178 | 177 | 176 | 174 | 174 | 172 | 171 | 169 | 159 | 150 | 150 | 148 | 148 | 128 | 128 | 126 | 122 | 123 | 122 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 183.3% | 73.00 | -88.02 | -223 | -300 | -300 | -198 | -102 | 34.00 | 156 | 109 | 136 | -0.22 | -111 | -87.33 | -111 | -87.20 | -62.11 | -104 | -68.94 | -68.85 | -70.25 |
| Share Based Compensation | 1.4% | 206 | 204 | 207 | 217 | 172 | 114 | 253 | 125 | 162 | 201 | 153 | 159 | 142 | 122 | 108 | 76.00 | 69.00 | 64.00 | 60.00 | 57.00 | 51.00 |
| Cashflow From Investing | 40.2% | 156 | 111 | 74.00 | 211 | 96.00 | -719 | -1,082 | -1,467 | -1,401 | -613 | -702 | -1,233 | -392 | -489 | -124 | 704 | -232 | -260 | -782 | -747 | -795 |
| Cashflow From Financing | -22.8% | 160 | 207 | 76.00 | 54.00 | 54.00 | 4.00 | 8.00 | 901 | 905 | 907 | 1,880 | 1,006 | 1,003 | 993 | 253 | 256 | 274 | 502 | 934 | 928 | 911 |
EXAS Income Statement
2023-06-30Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Income Statement [Abstract] | ||||
| Revenue | $ 622,093 | $ 521,640 | $ 1,224,543 | $ 1,008,211 |
| Operating expenses | ||||
| Cost of sales (exclusive of amortization of acquired intangible assets) | 156,991 | 144,600 | 313,857 | 279,305 |
| Research and development | 104,095 | 106,083 | 199,514 | 208,331 |
| Sales and marketing | 176,490 | 215,922 | 363,454 | 448,103 |
| General and administrative | 237,965 | 181,672 | 455,260 | 351,442 |
| Amortization of acquired intangible assets | 22,929 | 26,356 | 45,857 | 51,010 |
| Impairment of long-lived assets | 552 | 6,591 | 621 | 6,591 |
| Total operating expenses | 699,022 | 681,224 | 1,378,563 | 1,344,782 |
| Loss from operations | (76,929) | (159,584) | (154,020) | (336,571) |
| Other income (expense) | ||||
| Investment income (loss), net | 4,828 | (3,719) | 5,318 | (5,206) |
| Interest expense | (7,818) | (4,511) | (3,711) | (8,989) |
| Total other income (expense) | (2,990) | (8,230) | 1,607 | (14,195) |
| Net loss before tax | (79,919) | (167,814) | (152,413) | (350,766) |
| Income tax benefit (expense) | (1,107) | 1,751 | (2,764) | 3,766 |
| Net loss | $ (81,026) | $ (166,063) | $ (155,177) | $ (347,000) |
| Net loss per share—basic (in usd per share) | $ (0.45) | $ (0.94) | $ (0.87) | $ (1.98) |
| Net loss per share—diluted (in usd per share) | $ (0.45) | $ (0.94) | $ (0.87) | $ (1.98) |
| Weighted average common shares outstanding—basic (in shares) | 180,204 | 176,364 | 179,393 | 175,396 |
| Weighted average common shares outstanding—diluted (in shares) | 180,204 | 176,364 | 179,393 | 175,396 |
EXAS Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 604,363 | $ 242,493 |
| Marketable securities | 171,349 | 389,564 |
| Accounts receivable, net | 178,317 | 158,043 |
| Inventory | 130,770 | 118,259 |
| Prepaid expenses and other current assets | 89,129 | 73,898 |
| Total current assets | 1,173,928 | 982,257 |
| Long-term Assets: | ||
| Property, plant and equipment, net | 686,602 | 684,756 |
| Operating lease right-of-use assets | 148,690 | 167,003 |
| Goodwill | 2,346,248 | 2,346,040 |
| Intangible assets, net | 1,910,559 | 1,956,240 |
| Other long-term assets, net | 89,536 | 90,577 |
| Total assets | 6,355,563 | 6,226,873 |
| Current liabilities: | ||
| Accounts payable | 75,080 | 74,916 |
| Accrued liabilities | 299,586 | 299,216 |
| Operating lease liabilities, current portion | 29,872 | 28,366 |
| Loans Payable, Current | 50,000 | 0 |
| Other current liabilities | 33,519 | 10,249 |
| Total current liabilities | 488,057 | 412,747 |
| Long-term liabilities: | ||
| Convertible notes, net | 2,311,567 | 2,186,106 |
| Long-term debt, less current portion | 0 | 50,000 |
| Other long-term liabilities | 330,816 | 352,459 |
| Operating lease liabilities, less current portion | 168,501 | 182,399 |
| Total liabilities | 3,298,941 | 3,183,711 |
| Commitments and contingencies (Note 14) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.01 par value Authorized—5,000,000; shares issued and outstanding—no shares at June 30, 2023 and December 31, 2022 | 0 | 0 |
| Common stock, $0.01 par value Authorized—400,000,000; shares issued and outstanding—180,545,663 and 177,925,631 shares at June 30, 2023 and December 31, 2022 | 1,806 | 1,780 |
| Additional paid-in capital | 6,475,742 | 6,311,644 |
| Accumulated other comprehensive loss | (723) | (5,236) |
| Accumulated deficit | (3,420,203) | (3,265,026) |
| Total stockholders’ equity | 3,056,622 | 3,043,162 |
| Total liabilities and stockholders’ equity | $ 6,355,563 | $ 6,226,873 |
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.